Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 795 results for mental health

  1. Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)

    Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

  2. Rehabilitation after critical illness in adults (CG83)

    This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.

  3. Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.

  4. Unintentional injuries in the home: interventions for under 15s (PH30)

    This guideline covers home safety assessments, supplying and installing safety equipment and providing education and advice. It aims to prevent unintentional injuries among all children and young people aged under 15 but, in particular, those living in disadvantaged circumstances.

  5. Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)

    This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.

  6. Cardiovascular risk assessment and lipid modification (QS100)

    This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.

  7. Specialist neonatal respiratory care for babies born preterm (QS193)

    This quality standard covers neonatal respiratory support in hospital for babies born preterm (before 37 weeks of pregnancy). It describes high-quality care in priority areas for improvement.

  8. Investing in line managers

    existing line manager induction training against NICE guidance on workplace health: management practices . The training is updated to...

  9. Oral health in care homes (QS151)

    This quality standard covers oral health, including dental health and daily mouth care, for adults in care homes (with and without nursing provision). It describes high-quality care in priority areas for improvement.

  10. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

  11. Sustainability

    NICE is committed to supporting the national agenda for achieving a sustainable health and care system.

  12. Stage 5: discharge and transferring care

    Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.

  13. Palliative care for adults: strong opioids for pain relief (CG140)

    This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by NICE's guideline on care of dying adults in the last days of life .

  14. Developing and updating local formularies (MPG1)

    This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.

  15. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.